Abstract Details

Title H-FABP as a Biomarker of Vascular Brain Damage in Transient Ischemic Attack

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) P3 - Poster Session 3 (5:30 PM-6:30 PM)

Poster/Presentation
Number 5-009

Background The accurate diagnosis of transient ischemic attack (TIA) appears to be a challenge in clinical practice.

Objective

Our objective was to explore the potential value of heart fatty-acid binding protein (H-FABP) for the differential diagnosis of TIA versus mimics.

Design/Methods A retrospective analysis with data from two large prospective cohorts was performed. We selected 175 patients from the StrokeChip multicenter study and 91 patients from a blood sample collection including patients diagnosed with TIA and available diffusion-weighted imaging (DWI) data. Blood was collected within 6 or 24 hours of symptom onset respectively. H-FABP was measured using a rapid Point-of-care-test (POCT). Biomarker levels were compared between TIA and mimics, and between positive and negative DWI lesions. Accuracy was evaluated with Receiver-operating-characteristic (ROC) curves. Cut offs were obtained using PanelomiX algorithms.

Results H-FABP levels were higher in patients with TIA compared to mimic [3.10 ng/mL (IQR 2.13 – 4.78) versus 1.70 ng/mL (IQR 1.23-2.38)] p <0.001. Discrimination Area under the curve (AUC) was 0.74 (95% CI: 0.64 – 0.83). The PanelomiX algorithm selected a cut off of >1.55ng/ml for H-FABP, and age >41.5 years; with a sensitivity of 89.00% and a specificity of 54.80%. A trend to higher concentrations was observed in those with acute DWI lesions [3.20 (IQR 2.40-4.10) vs. 2.40 (IQR 1.90–3.77) p=0.17].

Conclusions

H-FABP could emerge as a potential diagnostic biomarker in clinical practice due to its ability to discriminate between patients with and without TIA. The quick and easy performance of POCT measurements allows its implementation in emergency departments and even in primary care centers.

Authors/Disclosures
Daisy Guamán (UAB) PRESENTER	Miss Guamán has nothing to disclose.
Elena Palà	No disclosure on file
Paula García	No disclosure on file
Anna Penalba	No disclosure on file
Marcel Lamana (VHIR)	No disclosure on file
Alejandro Bustamante (Hospital Universitari Germans Trias i Pujol)	No disclosure on file
Jean-Charles Sanchez	No disclosure on file
Sandrine Reymond	No disclosure on file
Leire Azurmendi	No disclosure on file
Soledad Pérez Sánchez	No disclosure on file
Marta Rubiera (Hospital U. Vall d'Hebron)	No disclosure on file
Elvira Chocano	No disclosure on file
Joan Montaner	No disclosure on file
Alex Rovira	Alex Rovira has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Alex Rovira has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofy. Alex Rovira has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Alex Rovira has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Alex Rovira has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Alex Rovira has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Alex Rovira has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Alex Rovira has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Alex Rovira has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Alex Rovira has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Alex Rovira has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bristol Myers. Alex Rovira has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer. Alex Rovira has stock in Tensor Medical.